Partnership with MMV in Anti-Malarial Drug Discovery

Iktos entered a collaboration with Medicines for Malaria Venture (MMV), described as "a leading product development partnership (PDP) in the field of antimalarial drug research and development." Under the agreement, Iktos will deploy its "DockAI" technology to accelerate identification of new antimalarial drug candidates, supporting MMV's mission in this therapeutic area. No specific financial figures, timelines, or quantified outcomes are provided in the page content (found via a corrected URL path, not the one supplied).

Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.